AstraZeneca to outsource all manufacturing within next decade: report

Share this article:

AstraZeneca said it plans to outsource all of its drug manufacturing within the next 10 years, The Times of London reports.

“Manufacturing for AstraZeneca is not a core activity,” said David Smith, AstraZeneca's EVP of operations, in a report on the newspaper's Web site.

“AstraZeneca is about innovation and brand building … There are lots of people and organizations that can manufacture better than we can,” Smith added.

Smith is reportedly leading a restructuring at the company aimed at cutting costs and improving profitability.

He told The Times that the company's priority would be to outsource all of its manufacturing of active pharmaceutical ingredients.

This year to date, the Anglo-Swedish drugmaker has announced plans to phase out 7,600 staff, nearly 12% of its workforce, to help save the company an estimated $900 million by 2010.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.